Gsk Share Discussion Threads

[netcurtains] 11/8/2022 10:12

Div Yield now 6.4% (PE ratio about 10.9)...
I've just bought some.

[action] 11/8/2022 10:05

Or will come back with lower offer for Haleon

[careful] 11/8/2022 09:49

So the legal case is based upon the argument that contaminated Zantac could be the cause of several cancers.
Millions get cancer who do not take Zantac, so how can it be proven?
Another dodgy statistical analysis I assume, here we go again after the dodgy Covid numbers.

If the case is lost up $500,000 per claimant can be expected depending upon individual cases.
This will cost billions if it goes the wrong way.

Maybe the Covid anti vax lobby were wiser than the rest of us after all.

GSK is accident prone.

Not sure why the consumer spin off HLN is suffering even more.

The trial is in Woke California. Oh Dear.

[spyder] 11/8/2022 09:47

Goodness, who would ever have imagined that we would see GSK back in the £14s - looks likely soon.

[alphorn] 11/8/2022 09:31

TM #333. In this industry any lost time can be very costly due to competition in drug development.....and lost time there will be. I am negative on the demerger and closed out my GSK positions well prior the demerger as posted. It may be the time to reopen some?

[jretlaw] 11/8/2022 09:27

Hope this is not another indvidior plc case litigation Emma and whole board must now go

[montyhedge] 11/8/2022 09:21

Unilever dodged a bullet.

[tradermichael] 11/8/2022 09:16

spyder - the value of a business is not always measured by its immediate share price ("market capitalisation"). Unilever's offer was turned down by GSK and they failed to increase their offer (even though we don't know the details e.g. transfer of debt etc).

Accordingly, Unilever lost a once-in-a-lifetime opportunity to acquire a world-leading consumer healthcare business. Their risk now is that you may see Unilever itself eventually broken up and sold off in parts.

[spyder] 11/8/2022 08:25

Haleon’s Execs need to tell its shareholders what the position is, the shares are down another 5% this morning.
Unilever shareholders must be mighty relieved.

[spyder] 11/8/2022 08:22

And while we are on the subject, why are GSK & HLN both going down in equal measure? Who has ongoing responsibility for the Zantac liability? Why would it be both companies??

[spoole5] 11/8/2022 08:16

Anyone gonna take some responsibility and make a statement?

[tuftymatt] 11/8/2022 08:14

Let's hope that last bit is right!!

[spyder] 11/8/2022 08:12

And the falls resume.
At some point, some explanation will be required as it is odd to see a total news vacuum in the face of such relentless falls, if is is as a result of the Zantac litigation, the company should at least let us know its position rather than the usual “we don’t comment on ongoing litigation” none sense.
August madness.

[tradermichael] 11/8/2022 08:10

spyder, its simply because the drug doesn't meet all the endpoints.

Sotrovimab is not authorized for use in adult or pediatric patients who:
are hospitalized due to COVID-19, OR
require oxygen therapy and/or respiratory support due to COVID-19, OR
require an increase in baseline oxygen flow rate and/or respiratory support due to COVID-19 in those patients on chronic oxygen.

Benefit of treatment with sotrovimab has not been observed in patients hospitalized due to COVID‑19. SARS-CoV-2 monoclonal antibodies may be associated with worse clinical outcomes when administered to hospitalized patients with COVID‑19 requiring high-flow oxygen or mechanical ventilation.

That is the reason for this so-called class action, a pretty weak case, easily defended against the following:

On August 9, 2022, Vir Biotechnology, Inc. (“Vir”), GSK’s development partner for the proposed COVID-19 treatment sotrovimab, issued a press release disclosing that that Vir “and GSK do not plan to file a Biologics License Application for sotrovimab at this time and do not intend to pursue the US-based Phase 3 COMET-STAR prophylaxis trial. Discussions with the FDA remain ongoing regarding the appropriate path forward for sotrovimab in the US.” On this news, GSK’s American Depositary Receipt price fell sharply during intraday trading on August 10, 2022.

[spoole5] 11/8/2022 08:05

Heads gonna have to roll soon

[spyder] 11/8/2022 07:55

This is very odd ... 2 US law firms have launched a class action case against officers of GSK in relation to securities fraud as a result of yesterday’s 4%+ fall in the ADRs.
They site the reason as being VIR’s & GSK’s decision not to pursue a licence for sotrovimab.
See here for an example - www.bgandg.com/gsk
I’m not sure I understand why?

[patientcapital] 11/8/2022 07:44

Much as I observed the other day. Investors will be chopping and changing, repositioning themselves according to their individual requirements, investment criteria and so on. Doesn't offer any short term comfort, granted!

[tradermichael] 11/8/2022 07:42

With a demerger like this, don't expect an instant outcome. It will take a considerable length of time for the benefits to show .....

[ceaserxzy] 10/8/2022 18:18

looks like splitting company is not the panacea it pretended to be, if they are still being run by the same incompetent managements. It could be worse with job roles and therefore costs as well as hardware systems duplicated without any gains in operational efficiency.

[shalder] 10/8/2022 17:37

All this despite Emma acquiring 16 shares!:)

[jonjoneil] 10/8/2022 17:29

I didn't expect Elliott's exit to be so brutal!

[zho] 10/8/2022 17:12

>>Ex divi tomorrow...>>

"The ex-dividend date will be 18 August 2022, with a record date of 19 August 2022 and a payment date of 6 October 2022."

[spyder] 10/8/2022 17:10

Big volume today.
Wait for the headlines tomorrow - “Elliott exits GSK & Haleon”
The shares look excellent value at these levels, the only other concern I have is the Zantac litigation.

[supermarky] 10/8/2022 17:03

xd is 18 August 2022